Compare funds
Evaluate funds side by side, to find the best fit for your investment goals.
The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the NASDAQ Biotechnology Index. The Index measures the performance of companies listed on the NASDAQ Stock Market that are classified as either biotechnology companies or pharmaceutical companies, according to their Industry Classification Benchmark (ICB) and that also meet other eligibility criteria as determined by NASDAQ, Inc. (the Index Provider), including minimum market capitalisation and liquidity requirements.
View fundThe investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the NASDAQ Biotechnology Index. The Index measures the performance of companies listed on the NASDAQ Stock Market that are classified as either biotechnology companies or pharmaceutical companies, according to their Industry Classification Benchmark (ICB) and that also meet other eligibility criteria as determined by NASDAQ, Inc. (the Index Provider), including minimum market capitalisation and liquidity requirements.
View fundKey takeaways
The ETFs track the same security, and so are effectively the same fund. £BTEK is traded in British pounds (£) on the London Stock Exchange, while $BTEC is traded in US dollars ($) on the same exchange.
Fund highlights
Fund name | iShares Nasdaq US Biotechnology | iShares Nasdaq US Biotechnology |
|---|---|---|
USD | GBP | |
USD | USD | |
| Accumulating | Accumulating | |
Fund size | $1.1bn | £812m |
| 0.92 | - | |
Last price | $9.49 | £7.11 |
| 0.35% | 0.35% | |
Fund manager | BlackRock | BlackRock |
Benchmark | NASDAQ Biotechnology Index (Net Total Return) | NASDAQ Biotechnology Index (Net Total Return) |
Risk | ||
Ticker | $BTEC | £BTEK |
Primary listing | LSE | LSE |
Documents | $BTEC Key Information Document | £BTEK Key Information Document |
Market data provided by CBOE Europe and Deutsche Börse.
Performance
CumulativeRolling yearsLump sum investment
$BTEC
£BTEK
Past performance is no guarantee of future returns.
The “cumulative” calculation shows returns on a price basis (i.e. excluding dividends). If an instrument trades in a different currency from your home currency, currency fluctuations may affect returns. These instruments are traded in different currencies, and performance is shown in the instruments' trading currencies
Sector exposure
ChartTable
$BTEC
£BTEK
Top holdings
Amgen
8.01%
Vertex Pharmaceuticals
8.00%
Gilead Sciences
7.36%
Regeneron
4.90%
Revolution Medicines
2.78%
Alnylam Pharmaceuticals
2.51%
Biogen
2.14%
Illumina
1.98%
Royalty Pharma
1.81%
Other
60.51%
Amgen
8.01%
Vertex Pharmaceuticals
8.00%
Gilead Sciences
7.36%
Regeneron
4.90%
Revolution Medicines
2.78%
Alnylam Pharmaceuticals
2.51%
Biogen
2.14%
Illumina
1.98%
Royalty Pharma
1.81%
Other
60.51%
Invest in $BTEC or £BTEK on Lightyear
Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.